Member: RADAR on Specialty Pharmacy

We would love your feedback!

January 1, 2021

RADAR on Specialty Pharmacy strives to provide strategic information on specialty drugs for pharmaceutical companies, pharmacy directors, MCOs, PBMs, industry consultants and clinicians. Please let us know how we’re doing — and what we can do better — by taking this brief reader survey. CLICK HERE for the survey

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Centene Boosts Specialty Drug Expertise With Pair of Deals

January 1, 2021

Centene Corp. celebrated the end of 2020 by closing on its acquisition of specialty pharmacy PANTHERx Rare, LLC on Dec. 30, then started 2021 with an agreement to acquire Magellan Health, Inc. The deals will strengthen Centene’s expertise in the specialty pharmacy space, particularly in the burgeoning orphan drug space by bringing onboard PANTHERx, an experienced company that’s shown remarkable growth over the past 10 years.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Race for COVID Vaccines, Therapies Topped Past Year’s Trends

January 1, 2021

As we look back over the past year, the COVID-19 pandemic has been top of mind for many involved in pharma commercialization and coverage. Less than a year after scientists sequenced the COVID genome, the FDA granted emergency use authorization to vaccines from Pfizer Inc./BioNTech SE and Moderna, Inc. in December — an unprecedented time frame for vaccine development, testing and rollout. Shortly thereafter, vaccinations started to be administered. AIS Health spoke with a variety of industry experts on COVID-related trends over the past year.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

FDA Approves First Oral Therapy For Prevention of HAE Attacks

With Chart: Requiring a prior authorization for berotralstat is the most likely indicated anticipated management requirement upon FDA approval

January 1, 2021

When the FDA approved BioCryst Pharmaceuticals, Inc.’s Orladeyo (berotralstat) last month, the drug became the first oral treatment for prophylaxis to prevent hereditary angioedema (HAE) attacks. According to Zitter Insights, payers with nearly three-quarters of covered lives plan to manage it at parity to other prophylactic treatments.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Innovative Drugs Were Some Top 2020 Specialty Trends

January 1, 2021

While the COVID-19 pandemic and pharma’s efforts to counter it were the top pharma concerns in 2020, that wasn’t the only innovation within the specialty pharmacy arena. AIS Health spoke with a variety of industry experts on various trends over the past year.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.